Oslo, Norway, 17 March 2021 – Targovax ASA (OSE: TRVX) announces that the General meeting has elected seasoned industry expert Sonia Quaratino MD PhD as new member of the Board of Directors.
Dr Quaratino is an R&D executive with over 20 years’ experience in clinical development and immunology research. She is Chief Medical Officer at Kymab, a clinical-stage biopharmaceutical company recently acquired by Sanofi with a deal value of approx. USD 1.5bn. She is also the Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics. Prior to her role at Kymab, Dr Quaratino held a position as Global Clinical Program Leader – Translational Clinical Oncology at Novartis, responsible for the clinical development of proprietary therapeutic antibody programs in immuno-oncology. Prior to this, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators.
Dr Quaratino has an extensive professional background which includes a Medical Degree and a Doctorate in Hematology-Oncology from the University of Palermo, Italy and a PhD in Immunology from Imperial College London, UK. For a number of years, she was a Professor of Immunology at the University of Southampton, a leading institution for innovative research. During Dr Quaratino’s time in Southampton her focus was on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
Chairman of the Nomination Committee, Mr. Ludvik Sandnes says: “We are very pleased to have attracted Dr Quaratino as new member of the Board. Dr Quaratino has an impressive track record in clinical development and immunology research. In its current phase of development, Targovax requires international competence on all levels. Dr Quaratino brings both experience from big pharmaceutical companies as well as a clinical-stage development company. Her research background is also of great interest to us, as it supplements the knowledge base in the Board.”
Dr Quaratino is replacing Dr Wheeler. Targovax expresses the company’s gratitude for the excellent work Dr Wheeler has done as member of the Board over the past years.
For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz – LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.